Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM

Phase 3

Recruiting

• Conditions: dm
• Interventions: Drug: vildagliptin\metformin; Drug: Vildagliptin

• Registration Number: NCT03925701
• Lead Sponsor: Sherief Abd-Elsalam

Brief Summary

Clinical study evaluating vildagliptin versus vildagliptin/metformin on NAFLD with DM.

Detailed Description

Clinical study evaluating vildagliptin versus vildagliptin/metformin on nonalcoholic fatty liver disease with DM.

Study Timeline

• Status Verified: 2019-04
• Study Start: 2019-04-01
• Study First Submitted: 2019-04-22
• Study First Submitted QC: 2019-04-23
• Study First Posted: 2019-04-24
• Last Update Submitted: 2019-04-26
• Last Update Posted: 2019-04-29
• Primary Completion: 2028-12
• Study Completion: 2028-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• NAFLD and type 2 DM

Exclusion Criteria

• Viral hepatitis.
• Child score more than 6.
• renal impairment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
vildagliptin\metformin	vildagliptin\metformin	vildagliptin\\metformin twice daily
vildagliptin	Vildagliptin	vildagliptin 50 mg twice daily

Primary Outcome Measures

Name	Time	Method
number of patients with improved nafld and insulin resistance	6 months	number of patients showing improved nafld and insulin resistance

Trial Locations

Locations (1)

Tanta University; 🇪🇬 Tanta, Egypt